http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102858771-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b65747ed78f05dd9ebe107b50ce2855
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 2011-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad43f564b1c287018e5eb5d3cf9a9363
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b56cc64e841f591b7b5d78f717240a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d805f71d6972b2240205ca22e7a54051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f717d8e7401cb14c1ffc1aa6112eff55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_216e08cdf8793f035e3297b3a9c4bdf3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af4ec061f5686d42c8cdf7f41eb92f4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44d86197080073d57164d232e6bebadf
publicationDate 2013-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102858771-A
titleOfInvention 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivatives and their use as HIV integrase inhibitors
abstract The present invention provides novel 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivatives, pharmaceutically acceptable salts thereof, or solvates thereof useful as anti-HIV agents . The present invention relates to a compound represented by the following general formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof [in the formula, each symbol is as defined in the specification].
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112574155-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10221186-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103736081-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016090545-A1
priorityDate 2010-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006116764-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005016927-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010000032-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004024078-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466850945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467143748
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466946597

Total number of triples: 37.